- In March 2025, Abbott unveiled new data from the TRILUMINATE Pivotal Trial at ACC.25, reinforcing the clinical benefits of its TriClip transcatheter edge-to-edge repair system for treating tricuspid regurgitation. The study showed sustained improvements in quality of life and reduced heart failure hospitalizations over two years. This development strengthens Abbott’s leadership in the structural heart market and highlights growing confidence in minimally invasive tricuspid valve solutions
- In April 2024, the U.S. FDA approved Abbott’s TriClip G4 System, making it the first-ever FDA-approved device specifically designed for transcatheter treatment of tricuspid regurgitation. This approval marks a major regulatory milestone and opens access to a previously underserved patient population with limited surgical options. Abbott’s continued innovation in the TEER (Transcatheter Edge-to-Edge Repair) segment strengthens its competitive position globally in the tricuspid valve repair space
- In February 2024, Edwards Lifesciences received FDA approval for its EVOQUE Tricuspid Valve Replacement System, a breakthrough device that provides a minimally invasive alternative to open-heart surgery. Clinical results from the TRISCEND II trial showed near-complete elimination of tricuspid regurgitation in patients post-procedure. This approval positions Edwards as a frontrunner in the transcatheter tricuspid valve replacement market
- In June 2025, the Stony Brook Heart Institute launched a dedicated Transcatheter Tricuspid Valve Replacement (TTVR) Program, offering both TriClip and EVOQUE procedures for patients with severe tricuspid regurgitation. The program reflects increasing institutional investments in structural heart programs and highlights the accelerating pace of minimally invasive cardiac care in the U.S.
